Immune-based Therapies
A novel prognostic nomogram for predicting survival in diffuse pleural mesothelioma
Pathology 2023 February 4 [Link] Yagiz Aksoy, Angela Chou, Mahiar Mahjoub, Amy Sheen, Loretta Sioson, Mahsa S Ahadi, Anthony J Gill, Talia L Fuchs Abstract Recent advances in the management of diffuse pleural mesothelioma (DPM) have increased interest in prognostication and risk stratification on the basis that maximum benefit of combination immunotherapy appears to be…
Read MoreAdd-On Effect of Hemagglutinating Virus of Japan Envelope Combined with Chemotherapy or Immune Checkpoint Inhibitor against Malignant Pleural Mesothelioma: An In Vivo Study
Cancers 2023 February 1 [Link] Kazuma Sakura, Masao Sasai, Soichiro Funaki, Yasushi Shintani, Meinoshin Okumura, Yasufumi Kaneda Abstract Malignant pleural mesothelioma (MPM) is a refractory tumor because most of the lesions are already disseminated at diagnosis. Previously, the main treatment for MPM was combination chemotherapy. However, recently, immune checkpoint inhibitors (ICIs) are also used. For…
Read MoreCD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma
The Journal of Pathology. Clinical Research 2023 February 8 [Link] Shingo Inaguma, Akane Ueki, Jerzy Lasota, Masayuki Komura, Asraful Nahar Sheema, Piotr Czapiewski, Renata Langfort, Janusz Rys, Joanna Szpor, Piotr Waloszczyk, Krzysztof OkoĊ, Wojciech Biernat, David S Schrump, Raffit Hassan, Markku Miettinen, Satoru Takahashi Abstract Diffuse pleural mesothelioma (PM) is a highly aggressive tumour typically…
Read MoreGenomic Instability and Pro-Tumoral Inflammation are associated with Primary Resistance to Anti-PD1 + Anti-Angiogenesis in Malignant Pleural Mesothelioma
Cancer Discovery 2023 January 20 [Link] Francois-Xavier Danlos, Matthieu Texier, Bastien Job, Severine Mouraud, Lydie Cassard, Capucine Baldini, Andrea Varga, Andrey A Yurchenko, Audrey Rabeau, Stephane Champiat, Diane Letourneur, Delphine Bredel, Sandrine Susini, Yuna Blum, Aurelien Parpaleix, Cedric Parlavecchio, Lambros Tselikas, Jean-Eudes Fahrner, Anne-Gaelle Goubet, Mathieu Rouanne, Saloomeh Rafie, Alae Abbassi, Ines Kasraoui, Marie Breckler,…
Read MoreThiolate DNAzymes on Gold Nanoparticles for Isothermal Amplification and Detection of Mesothelioma-derived Exosomal PD-L1 mRNA
Analytical Chemistry 2023 January 9 [Link] Sareh Zhand, Ying Zhu, Hojjatollah Nazari, Mohammad Sadraeian, Majid Ebrahimi Warkiani, Dayong Jin Abstract Catalytic DNAzymes have been used for isothermal amplification and rapid detection of nucleic acids, holding the potential for point-of-care testing applications. However, when Subzymes (universal substrate and DNAzyme) are tethered to the polystyrene magnetic microparticles…
Read MoreEfficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention
International Journal of Clinical Oncology 2023 January 7 [Link] Akifumi Nakamura, Masaki Hashimoto, Nobuyuki Kondo, Seiji Matsumoto, Ayumi Kuroda, Toshiyuki Minami, Kazuhiro Kitajima, Kozo Kuribayashi, Takashi Kijima, Seiki Hasegawa Abstract Background: Treatment of recurrent malignant pleural mesothelioma (MPM) remains challenging. Our study examined the efficacy, tolerability, and safety of nivolumab with ipilimumab treatment for recurrent…
Read MoreTislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
Medicine 2022 December 30 [Link] Dandan Zhang, Jianping Liang, Yanhua Lv, Xikun Huang, Weihong Guo Abstract Rationale: Malignant pleural mesothelioma (MPM) is a malevolent tumor originated from pleura and often leads to poor prognosis. Chemotherapy of pemetrexed and cisplatin combined with antiangiogenic therapy of bevacizumab is recommended as the first-line regimen by guidelines. However, there…
Read MoreA Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma
JTO Clinical Case Reports 2022 December 1 [Link] Andreas Rimner, Prasad S Adusumilli, Michael D Offin, Stephen B Solomon, Etay Ziv, Sara A Hayes, Michelle S Ginsberg, Jennifer L Sauter, Daphna Y Gelblum, Annemarie F Shepherd, David M Guttmann, Jordan E Eichholz, Zhigang Zhang, Erika Ritter, Phillip Wong, Afsheen N Iqbal, Robert M Daly, Azadeh…
Read MoreClinical efficacy and safety of nivolumab in malignant non-pleural mesothelioma: A multicenter, open-label, single-arm, Japanese phase II trial (VIOLA) protocol
Oncology 2022 December 23 [Link] Kozo Kuribayashi, Masataka Igeta, Takashi Daimon, Ibu Maede, Shinichiro Suna, Rika Okamoto, Takashi Kijima Abstract Background: There is no authorized treatment for malignant non-pleural mesothelioma (MNPM) worldwide. In contrast to malignant pleural mesothelioma (MPM), MNPM has not been investigated, and no treatment has been established due to its rarity. Objectives:…
Read MoreThe STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model
Frontiers in Immunology 2022 November 18 [Link] Peter T Graham, Anna K Nowak, Scott M J Cornwall, Irma Larma, Delia J Nelson Abstract We assessed the murine Stimulator of Interferon Genes (STING) agonist, DMXAA, for anti-mesothelioma potential using the AE17-sOVA model that expresses ovalbumin (OVA) as a neo tumor antigen. Dose response experiments alongside testing…
Read More